In the 13th International Congress on Antiphospholipid Antibodies (2010, Galveston, TX), the task force recommended testing for the IgA aB2GPI in patients with a clinical profile suggestive of APS and negative for the aPL that are included in the APS classification criteria (11). Here, CD79A is linked to autoimmune polyendocrinopathy.